To Evaluate the Efficacy and Safety of 'BRDE33-100' for the Temporary Correction of Moderate to Severe Nasolabial Folds

NCT ID: NCT07069920

Last Updated: 2025-07-17

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 128 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-14
• Study Completion Date: 2026-05-31

Brief Summary

This study aims to demonstrate the non-inferiority of BRDE33-100 to Soonsoofill in temporarily improving moderate to severe nasolabial folds.

Detailed Description

This confirmatory clinical trial aims to demonstrate the non-inferiority of 'BRDE33-100' by comparing and evaluating the efficacy and safety of 'BRDE33-100' with 'Soonsoofill'.

This study follows a split-face design in which both the investigational device and the control device are used for treatment in each subject-one on each nasolabial fold. Device allocation will be determined by opening sealed randomization envelopes prior to each treatment. Efficacy and safety assessments will be conducted for 24 weeks after the initial treatment, followed by an additional 24-week long-term follow-up period, for a total participation duration of 52 weeks. Efficacy assessments will include the Wrinkle Severity Rating Scale (WSRS), the Global Aesthetic Improvement Scale (GAIS), and a pain evaluation using the Visual Analogue Scale (VAS). Safety assessments will include adverse event monitoring, clinical laboratory testing, vital signs, and physical examinations. At each efficacy assessment visit, including the baseline, standardized photographs of the treatment area will be taken, and WSRS scoring will be performed by an independent evaluator based on these images.

Conditions

Nasolabial Folds

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

The experimental group

BRDE33-100

Group Type: EXPERIMENTAL

BRDE33-100

Intervention Type: DEVICE

BRDE33-100 will be injected once at Visit 2 (Baseline).

The control group

Soonsoofill

Group Type: ACTIVE_COMPARATOR

Soonsoofill

Intervention Type: DEVICE

Soonsoofill will be injected once at Visit 2 (Baseline).

Interventions

BRDE33-100

BRDE33-100 will be injected once at Visit 2 (Baseline).

Intervention Type: DEVICE

Soonsoofill

Soonsoofill will be injected once at Visit 2 (Baseline).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Male or female subjects aged between 19 and 75 years, inclusive, as of the date of written informed consent.
• Voluntarily decided to participate in the study and signed the informed consent form in writing
• Subjects who desire improvement in nasolabial folds and have a Wrinkle Severity Rating Scale (WSRS) score of 3 or 4.
• Subjects whose bilateral nasolabial folds appear visually symmetrical, although WSRS scores do not need to be identical on both sides.
• Subjects who agree to use appropriate contraception from the date of signing the informed consent form until 3 months after the end of the clinical trial. *Examples of acceptable contraception include: copper intrauterine device (IUD), hormone-releasing IUD, condoms, vasectomy, tubal ligation, spermicides, vaginal contraceptive film, subdermal implants, injectable contraceptives, female condoms, and oral contraceptives.
• Subjects who agree not to undergo any procedures or treatments that may affect the nasolabial folds during the study period.
• Subjects who are able to understand and comply with the study instructions and are available for the entire duration of the study.

Exclusion Criteria

• Received antithrombotic agents (except for low-dose aspirin [100 mg, up to 300 mg/day]) or nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to screening
• Used topical agents on the device application area within 4 weeks prior to screening or plans to use them during the study period, including corticosteroids, retinoids, alpha hydroxy acids, skin-whitening agents, or anti-wrinkle functional cosmetics. (- Topical corticosteroids for therapeutic purposes may be used for a short duration of up to 14 consecutive days.)
• Received invasive laser treatment, deep peeling procedures, or filler injections on the device application area within 24 weeks prior to screening.
• Received any wrinkle improvement procedures on the device application area within 24 weeks prior to screening, including:

• Botulinum toxin injections
• Soft-tissue augmentation
• Facial lifting surgery
• Dermabrasion
• Dermal photo-rejuvenation
• Received any wrinkle improvement procedures on the device application area within 1 year prior to screening, including facial augmentation using calcium hydroxylapatite or wrinkle treatment using approved fillers.
• Received an injection of calcium hydroxylapatite in the nasolabial fold area within 1 year prior to screening.
• Has permanent dermal implants such as Softform or silicone in the nasolabial fold area.
• Underwent facial lifting involving thread-based tissue fixation (e.g., thread lifting) that affected the nasolabial fold area within 1 year prior to screening
• Has taken medications that may affect skin hypersensitivity testing, including:

① First- or second-generation antihistamines (e.g., chlorpheniramine, hydroxyzine, cetirizine, fexofenadine, loratadine) within 7 days prior to screening

② Tricyclic antidepressants (e.g., imipramine, doxepin) within 11 days prior to screening

③ H2-receptor antagonists (e.g., ranitidine) within 1 day prior to screening

• Has scars, skin disorders, wounds, infections, inflammation, or other skin lesions in the nasolabial fold area that may affect the outcome of this clinical trial.
• Has a history of anaphylaxis or severe systemic allergic reactions.
• Has a history of hypertrophic scarring, keloid formation, or hyperpigmentation.
• Has a known hypersensitivity to Hyaluronic acid (HA).
• Has experienced adverse reactions to EMLA Cream or other lidocaine-based anesthetic products.
• Has or has had autoimmune diseases including AIDS, or is immunocompromised.
• Has clinically significant disorders of the cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous systems, or has psychiatric conditions that may affect participation in this clinical trial.
• Tested positive on the skin hypersensitivity test indicating hypersensitivity to the investigational device or control device at the time of screening.
• Participated in other clinical trial(s) within 30 days prior to screening
• Pregnant or breast-feeding women (women of childbearing potential must undergo a pregnancy test)
• Subjects who, due to physical, neurological, or psychological conditions, are unable to comply with all aspects of the screening, evaluation, treatment, and follow-up schedule.
• Subjects who are otherwise unable to communicate or follow instructions properly.
• Determined by the principal investigator to be unable to participate in the study for other reasons

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BRPharm Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jiye Kim, M.D., PhD

Role: PRINCIPAL_INVESTIGATOR

Wonju Severance Christian Hospital

Locations

Name: Wonju severance Christian hospital

Wŏnju, Gangwon-do, South Korea

Countries

South Korea

Other Identifiers

Revitrane HA24-01

Identifier Type: -

Identifier Source: org_study_id